Skip to main content

Advertisement

SpringerLink
Log in

Intracavitary therapies for mesothelioma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

  • The diagnosis of mesothelioma needs to be defined histologically.

  • The staging system has been recently redefined anatomically, but may not be applicable to extrapleural mesothelioma.

  • Further clinicopathologic studies need to be performed to molecularly classify the disease further, according to prognosis.

  • Intracavitary therapy has a definite role in the treatment of mesothelioma.

  • Randomized studies of intracavitary therapies are needed to define the best treatment option.

  • The role of complementary therapeutic modalities such as surgery and radiotherapy needs to be defined by randomized studies.

  • There is an urgent need to better understand the biology of mesothelioma, which may lead to more focus on molecularly relevant therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Antman KH. Current Concepts: Malignant mesothelioma. N Engl J Med 1980, 303:200–202.

    Article  PubMed  CAS  Google Scholar 

  2. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996, 14:1–12.

    Article  PubMed  CAS  Google Scholar 

  3. Gross-Goupil M, Ruffie P: Malignant pleural mesothelioma. Bull Cancer 1999, 3 (suppl):43–54. Key information for the clinician.

    PubMed  Google Scholar 

  4. Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996, 335:1950–1955.

    Article  PubMed  CAS  Google Scholar 

  5. Panteix G, Guillaumont M, Cherpin L, et al.: Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology 1993, 50:366–370.

    Article  PubMed  CAS  Google Scholar 

  6. Markman M. Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998, 25:356–60.

    PubMed  CAS  Google Scholar 

  7. Merrin C. Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J Urol 1978, 119:493–495.

    PubMed  CAS  Google Scholar 

  8. Mune T, Yasuda K, Ishii M, Matsunaga T, Miura K. Tetany due to hypomagnesemia induced by cisplatin and doxorubicin treatment for synovial sarcoma. [review]. Intern Med 1993, 32:434–437.

    PubMed  CAS  Google Scholar 

  9. Thompson SW, Davis LE, Kornfeld M, et al.: Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269–1275.

    Article  PubMed  CAS  Google Scholar 

  10. Verschraegen C, Conrad CA, Hong WK. Subacute encephalopathic toxicity of cisplatin. Lung Cancer 1995,13:305–309.

    Article  PubMed  CAS  Google Scholar 

  11. Rusch VW, Niedzwiecki D, Tao Y, et al.: Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 1992,10:1001–1006.

    PubMed  CAS  Google Scholar 

  12. Markman M, Cleary S, Pfeifle C, Howell SB: Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986, 58:18–21.

    Article  PubMed  CAS  Google Scholar 

  13. Aitini E, Pasquini E, Cavazzini G, et al.: Local treatment of malignant pleural mesothelioma with intracavitary cytosine-arabinoside and cisplatin [letter]. Ann Oncol 1992, 3:771–772.

    PubMed  CAS  Google Scholar 

  14. Markman M, Howell SB. Daily intraperitoneal administration of cytarabine in a patient with peritoneal mesothelioma. Cancer Drug Deliv 1985, 2:285–289.

    PubMed  CAS  Google Scholar 

  15. Aitini E, Cavazzini G, Pasquini E, et al.: Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study. Acta Oncol 1994, 33:191–194.

    PubMed  CAS  Google Scholar 

  16. Markman M, Kelsen D: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992, 118:547–50.

    Article  PubMed  CAS  Google Scholar 

  17. Hayashi T, Nasu Y, Aramaki K, et al.: A case of peritoneal malignant mesothelioma with disappearance of ascites result of intraperitoneal instillation of mitomycin C and oral administration of UFT. Gan to Kagaku Ryoho 1989, 16:2449–2452.

    PubMed  CAS  Google Scholar 

  18. Langer CJ, Rosenblum N, Hogan M, et al.: Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993, 32:204–208.

    Article  PubMed  CAS  Google Scholar 

  19. Ito H, Imada T, Kondo J, et al.: A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy. Jpn J Clin Oncol 1998, 28:145–148.

    Article  PubMed  CAS  Google Scholar 

  20. Nakano T, Chahinian AP, Shinjo M, et al.: Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999, 85:2375–2384. Provides much-needed documentation.

    Article  PubMed  CAS  Google Scholar 

  21. Verschraegen C, Le D, Kudelka A, et al.: Cisplatin and irinotecan for peritoneal mesothelioma. Proc Am Soc Clin Oncol 2001, 20:A2110. Excellent study.

    Google Scholar 

  22. Bleiberg H, Cvitkovic E: Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. [review]. Eur J Cancer 1996, 32A(suppl 3):S18-S23.

    Article  PubMed  CAS  Google Scholar 

  23. Rothenberg ML, Kuhn JG, Burris HA, et al.: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11:2194–2204.

    PubMed  CAS  Google Scholar 

  24. de Forni M, Bugat R, Chabot GG, et al.: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994, 54:4347–4354.

    PubMed  Google Scholar 

  25. Abigerges D, Chabot GG, Armand JP, et al.: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13:210–221.

    PubMed  CAS  Google Scholar 

  26. Verschraegen CF, Levy T, Kudelka AP, et al.: Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997, 15:625–631.

    PubMed  CAS  Google Scholar 

  27. Masuda N, Fukuoka M, Kusunoki Y, et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992:10:1225–1229.

    Google Scholar 

  28. Han I, Ling YH, al-Baker S, et al.: Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res 1993, 53:4913–4919.

    PubMed  CAS  Google Scholar 

  29. Khokhar AR, Wright K, Siddik ZH, Perez-Soler R: Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1, 2 diaminocyclohexane platinum (Ii) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol 1988, 22:223–227.

    Article  PubMed  CAS  Google Scholar 

  30. Khokhar AR, al-Baker S, Krakoff IH, Perez-Soler R: Toxicity and antitumor activity of cis-bis-carboxylato (trans-R,R-1,2-diaminocyclohexane) platinum(Ii) complexes Entrapped in Liposomes. Cancer Chemother Pharmacol 1989, 23:219–224.

    Article  PubMed  CAS  Google Scholar 

  31. Perez-Soler R, Yang LY, Drewinko B, et al.: Increased cytotoxicity and reversal of resistance to cisdiamminedichloro-platinum(Ii) with entrapment of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (Ii) in multilamellar lipid vesicles. Cancer Res 1988, 48:4509–4512.

    PubMed  CAS  Google Scholar 

  32. Perez-Soler R, Shin DM, Siddik ZH, et al.: Phase I clinical and pharmacological study of liposomeentrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997, 3:373–379.

    PubMed  CAS  Google Scholar 

  33. VerschraegenC, Mansfield P, Feig B, et al.: Phase I study of an intraperitoneal liposomal cisplatin analog (L-NDDP) for treatment of peritoneal carcinomatosis [abstract]. Proc ASCO 1999, 18:1405. Provides key data.

    Google Scholar 

  34. Perez-Soler R, Lopez-Berestein G, Lautersztain J, et al.: Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum(Ii). Cancer Res 1990, 50:4254–4259.

    PubMed  CAS  Google Scholar 

  35. Verschraegen C, Mansfield P, Feig B, et al.: Phase I study of an intraperitoneal liposomal cisplatin analog L-NDDP for treatment of peritoneal carcinomatosis [abstract]. Proc ASCO 1999, 18:A1405.

    Google Scholar 

  36. Westermann AM, Dubbelman R, Moolenaar WH, et al.: Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Ann of Oncol 1997, 8:801–802.

    Article  CAS  Google Scholar 

  37. WestermannAM, Dubbelman R, Baars JP, et al.: Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemother Pharmacol 2000, 46:57–62. Provides much-needed documentation.

    Article  PubMed  CAS  Google Scholar 

  38. Vlasveld LT, Taal BG, Kroon BB, et al.: Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother Pharmacol 1992, 29:405–408.

    Article  PubMed  CAS  Google Scholar 

  39. Ardizzoni A, Pennucci MC, Castagneto B, et al.: Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 1994, 17:80–82.

    Article  PubMed  CAS  Google Scholar 

  40. Boutin C, Nussbaum E, Monnet I, et al.: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994, 74:2460–2467.

    Article  PubMed  CAS  Google Scholar 

  41. Tani M, Tanimura H, Yamaue H, et al.: Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases. Surg Today 1998, 28:647–651.

    Article  PubMed  CAS  Google Scholar 

  42. Cain J, Nori D, Huvos A, Erlandson RA, et al.: The role of radioactive colloids in malignant peritoneal mesotheliomas. Gynecol Oncol 1983, 16:263–274.

    Article  PubMed  CAS  Google Scholar 

  43. Reuter K, Raptopoulos V, Reale F, et al.: Diagnosis of peritoneal mesothelioma: computed tomography, sonography, and fine-needle aspiration biopsy. Am J Roentgenol 1983,140:1189–1194.

    CAS  Google Scholar 

  44. Muensterer OJ, Averbach AM, Jacquet P, et al.: Malignant peritoneal mesothelioma. Case-report demonstrating pitfalls of diagnostic laparoscopy. Int Surg 1997, 82:240–243.

    PubMed  CAS  Google Scholar 

  45. Neuhaus SJ, Texler M, Hewett PJ, Watson DI: Port-site metastases following laparoscopic surgery. Br J Surg 1998, 85:735–7341.

    Article  PubMed  CAS  Google Scholar 

  46. Sebbag G, Yan H, Shmookler BM, et al.: Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000, 87:1587–1593.

    Article  PubMed  CAS  Google Scholar 

  47. Sauter ER, Langer C, Coia LR, et al.: Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995, 60:100–105.

    Article  PubMed  CAS  Google Scholar 

  48. Colleoni M, Sartori F, Calabro F, et al.: Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 1996, 82:53–56.

    PubMed  CAS  Google Scholar 

  49. Averbach AM, Sugarbaker PH: Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996, 81:193–211.

    PubMed  CAS  Google Scholar 

  50. Vlasveld LT, Gallee MP, Rodenhuis S, Taal BG: Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Cancer 1991, 27:732–734.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Gynecologic and Medical Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe, Box 401, 77030, Houston, TX, USA

    Claire F. Verschraegen MD

Authors
  1. Claire F. Verschraegen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verschraegen, C.F. Intracavitary therapies for mesothelioma. Curr. Treat. Options in Oncol. 2, 385–394 (2001). https://doi.org/10.1007/s11864-001-0043-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0043-3

Keywords

Search

Navigation